Viridian Therapeutics, Inc./DE Deferred Tax Assets, in Process Research and Development
Viridian Therapeutics, Inc./DE (VRDN) had Deferred Tax Assets, in Process Research and Development of $118.27 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $118.27M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $86.85M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $45.98M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $18.25M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $118.27M 10-K · filed 2026-02-26 |
| 2024-12-31 | $86.85M 10-K · filed 2026-02-26 |
| 2023-12-31 | $45.98M 10-K · filed 2026-02-26 |
| 2022-12-31 | $18.25M 10-K · filed 2025-03-03 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |